BrainGate

What BrainGate does

BrainGate is a multi-institutional research consortium developing an intracortical brain-computer interface (iBCI) to restore communication, mobility, and independence for people affected by paralysis, ALS, brainstem stroke, muscular dystrophy, and other neurologic conditions. The core platform is the investigational BrainGate2 Neural Interface System, which uses implanted microelectrode arrays in the motor cortex to record neural activity and decode intended movements and speech via machine learning algorithms (LSTM-based decoders, RNNs for bimanual control). On top of this platform, the consortium has built specialized products including a Speech Neuroprosthesis (99% word accuracy, 56 WPM in independent home use), a Handwriting BCI, an instantaneous Voice-Synthesis Neuroprosthesis (Nature 2025), a Movement Restoration BCI using functional electrical stimulation, and an Assistive Communication cursor/keyboard system.

The consortium is led by Dr. Leigh Hochberg (Director) and brings together Massachusetts General Hospital, Brown University, Stanford, UC Davis, Emory, the VA Providence Healthcare System, Baylor College of Medicine (joined May 2026), and Rice University (joined May 2026), with Dr. John Donoghue as a foundational figure. The go-to-market is exclusively clinical-trial-based: six U.S. investigational sites recruit participants with tetraplegia who live within a three-hour drive, for a 13-month study commitment. There is no commercial revenue; the device is investigational and provided at no cost, with operations funded by NIH, VA RR&D, DARPA, and private foundations. The consortium has produced 200+ peer-reviewed publications since 1995, including first-in-human demonstrations of high-bandwidth wireless iBCI, intracortical handwriting decoding, and 3,800+ hours of independent at-home use by an ALS participant.

Name

BrainGate

Legal name

BrainGate

Website

https://braingate.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

BrainGate is a multi-institutional research consortium developing an investigational intracortical brain-computer interface that decodes intended movement and speech from the motor cortex to restore communication and mobility for people with paralysis, ALS, and locked-in syndrome.

Ownership category

akta.pro rank

Product category

Neural Implants

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

Keywords

• Brain-computer interfaces
• Neural prosthetics
• Speech restoration
• Assistive communication
• Intracortical implants

Headquarters

HQ city

Stanford

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research funding and grants: BrainGate is a research consortium funded primarily through grants from government agencies (NIH, NSF, VA, DARPA), foundations (ALS Association, American Heart Association, Craig H. Neilsen Foundation, Doris Duke Charitable Foundation), and philanthropy. No commercial revenue is generated as the device remains investigational.

Pricing tiers

Distribution channels1 record

Marketing channels4 records

Core offering

BrainGate is a research consortium developing and clinically testing the investigational BrainGate2 Neural Interface System, an intracortical brain-computer interface that records neural activity from microelectrode arrays implanted in the motor cortex. The system decodes intended movements and speech using machine learning algorithms, powering specialized applications such as speech neuroprostheses, voice-synthesis neuroprostheses, handwriting BCIs, movement restoration via FES, and assistive cursor/keyboard control for people with paralysis. All offerings are limited by federal law to investigational use and are provided to clinical trial participants at no cost.

Product overview

BrainGate is an investigational brain-computer interface technology consortium developing multiple interconnected BCI products for people with paralysis and neurologic disease. The core offering is the BrainGate2 Neural Interface System, an intracortical microelectrode array that records neural signals to decode intended movements and speech. This platform powers several specialized applications: the Speech Neuroprosthesis for communication restoration, the Handwriting BCI and Voice Synthesis Neuroprosthesis for rapid text and voice output, the Movement Restoration BCI for limb control via FES, and the Assistive Communication BCI for cursor control. All products are investigational devices limited by federal law to clinical research use only.

Differentiator

Problem solved

Functional benefit

Brands

• BrainGate2: The second-generation BrainGate neural interface system used in ongoing clinical trials

Products and services

• BrainGate2 Neural Interface System Investigational intracortical brain-computer interface (iBCI) that records neural signals from microelectrode arrays implanted in the motor cortex, decoding intended movements and speech so people with paralysis can control computers, prosthetic limbs, and communication devices with their thoughts.
• Speech Neuroprosthesis BCI system that decodes neural signals responsible for speech production directly from the cortex, converting attempted speech into text or synthesized voice to restore fluent conversational communication for people with ALS, brainstem stroke, and anarthria.
• Voice Synthesis Neuroprosthesis Real-time voice synthesis system that converts neural signals into synthesized speech during attempted vocalized speech, providing auditory feedback to the user alongside text decoding.
• Handwriting Brain-Computer Interface BCI system that decodes imagined handwriting movements from neural signals to enable rapid text entry, achieving typing speeds more than twice as fast as traditional point-and-click BCI typing methods.
• Movement Restoration BCI Neuroprosthetic system that decodes intended movement signals from the motor cortex and sends commands to muscles via implanted stimulating electrodes (FES) to induce limb movement, restoring motor function for people with cervical spinal cord injury or brainstem stroke.
• Assistive Communication BCI Cursor and keyboard control system enabling people with locked-in syndrome to control computers and communicate by thinking about hand movements, as if controlling a computer mouse, without muscular movement.

Quantifiable outcome

• 99% word accuracy in speech decoding during independent home use
• +4 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core.

• Massachusetts General Hospital (MGH)coreStrategic or Co-development PartnerPrimary institutional partner and sponsor-investigator site. Dr. Leigh Hochberg serves as Director of BrainGate Consortium and Clinical Trials from MGH. The Center for Neurotechnology and Neurorecovery (CNTR) is based at MGH.
• Brown UniversitycoreStrategic or Co-development PartnerHome institution of Dr. John Donoghue (founder) and Dr. Leigh Hochberg. Robert J. & Nancy D. Carney Institute for Brain Science collaborates on neural interface research. Dr. Hochberg holds position as Professor of Engineering at Brown.
• Stanford UniversitycoreStrategic or Co-development PartnerClinical trial site led by Dr. Jaimie Henderson. Stanford Neural Prosthetics Translational Laboratory (NPTL) co-develops BCI technology. Stanford joined as clinical site in 2011.
• University of California, DaviscoreStrategic or Co-development PartnerClinical trial site and key research partner. UC Davis Neuroprosthetics Lab co-directed by Dr. David Brandman. Rice University and Baylor College of Medicine joined the consortium in May 2026.
• Emory UniversitycoreStrategic or Co-development PartnerClinical trial site led by Dr. Nicholas Au Yong, Associate Professor of Neurosurgery and Biomedical Engineering.
• VA Providence Healthcare SystemcoreStrategic or Co-development PartnerVA RR&D Center for Neurorestoration and Neurotechnology directed by Dr. Leigh Hochberg. Clinical trial site with Dr. Stephen Mernoff as co-investigator.
• Baylor College of MedicinecoreStrategic or Co-development PartnerMost recently added consortium partner in May 2026. Dr. Sameer Sheth serves as Principal Investigator, bringing expertise in cognitive neurophysiology and psychiatric neurosurgery.
• Rice UniversitycoreStrategic or Co-development PartnerJoined consortium in May 2026. Neuroengineering Initiative and Rice Brain Computer Interface Lab collaborate on neural interface research.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Synchron: Synchron develops the Stentrode, an endovascular brain-computer interface delivered through blood vessels, avoiding open brain surgery. It targets the same locked-in syndrome and paralysis patient population as BrainGate but with a fundamentally less invasive delivery mechanism and earlier commercial milestones.
• Neuralink: Neuralink develops implantable brain-computer interfaces using high-channel-count electrode arrays, targeting similar applications in motor control and speech restoration for paralysis patients. It is the most prominent direct competitor to BrainGate in the iBCI space, with significant private capital and a high-profile public profile.
• Precision Neuroscience: Precision Neuroscience is developing a minimally invasive cortical interface using a thin-film electrode array that sits on the brain surface. It targets motor and speech restoration applications overlapping with BrainGate, with a less invasive surgical approach.
• Paradromics: Paradromics is developing high-data-rate intracortical BCIs using novel electrode architectures for both medical and future consumer applications. It targets similar neural decoding use cases as BrainGate's motor cortex recordings and represents another well-funded iBCI competitor.
• Blackrock Neurotech: Blackrock Neurotech provides the Utah array hardware used in BrainGate's clinical trials and independently develops its own BCI systems for paralysis and communication restoration. It is both a technology supplier to BrainGate and a direct competitor pursuing commercial BCI deployment.

Emerging players

• Inbrain Neuroelectronics: Inbrain Neuroelectronics develops graphene-based neural interfaces for both decoding and stimulation applications in neurological disorders. It targets similar clinical indications as BrainGate (speech, motor restoration) with differentiated electrode materials.
• Motif Neurotech: Motif Neurotech is developing minimally invasive brain stimulation implants for psychiatric and neurological disorders. While focused more on therapeutics than communication BCIs, it represents an emerging player in the implantable neurotechnology space with adjacent technology.

Broad incumbents

• NeuroPace: NeuroPace is an established commercial neurotechnology company with FDA-approved responsive neurostimulation for epilepsy. It operates broadly in implantable neurological devices, overlapping with BrainGate's neurotherapeutics research area but not directly competing in speech/motor BCIs.
• Medtronic: Medtronic is a major medical device company with extensive neurological and brain stimulation products (deep brain stimulation, spinal cord stimulation). It serves as a broad incumbent in neurotechnology with the resources to enter the BCI market through acquisition or internal development.
• Abbott (Neuromodulation): Abbott's Neuromodulation division produces deep brain stimulation and spinal cord stimulation devices for neurological disorders. As a major incumbent in implantable neurotechnology, it represents a potential strategic acquirer or competitor with the scale to commercialize BCI technology globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/braingateteam
• Facebookfacebook.com/183450178344554
• LinkedInlinkedin.com/company/braingate-team

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainGate